data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Castle Biosciences

(NASDAQ:CSTL)

Intraday

$19.51

-0.35[-1.76%]

After-Hours

$19.51

0[0.00%]

Perks Buy Compare Brokers

$19.51

-0.35[-1.76%]

At close: Apr 25

$19.51

0[0.00%]

After Hours: 4:20PM EDT

Q1 2024 Earnings in 6 days from now on Thu May 2nd, after the market close

Conference call scheduled in 6 days at 16:30 PM Click to view the webcast

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Castle Biosciences Stock (NASDAQ:CSTL)

Castle Biosciences Stock (NASDAQ: CSTL)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, April 04, 2024

Castle Biosciences Plans To Share New Data At The 20Th European Association Of Dermato-Oncology Congress
Benzinga Newsdesk - Apr 4, 2024, 4:31PM

Friday, March 22, 2024

Castle Biosciences Gives Long-Term Outcomes Data Shared At SSO 2024 Show That Patients With A Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free At 3-Years, Including Those Who Utilized The Test To Help Guide the Decision To Avoid An SLNB
Benzinga Newsdesk - Mar 22, 2024, 4:34PM

Friday, March 15, 2024

Castle Biosciences New Study Showing The Drug-Drug Interactions And Lifestyle Factors Provided By ' IDgenetix Test Improve Medication Recommendations Over Drug-Gene Interactions Alone For Patients 65 And Older
Benzinga Newsdesk - Mar 15, 2024, 4:34PM

Friday, March 08, 2024

Castle Biosciences To Present New Data Highlighting The Clinical Value Of Its Dermatologic Tests For Patients With Skin Cancer At The 2024 American Academy Of Dermatology Annual Meeting
Benzinga Newsdesk - Mar 8, 2024, 4:32PM

Thursday, March 07, 2024

Castle Biosciences Announced The Publication Of A New Multi-center Performance Study Of Its DecisionDx-SCC Risk Stratification Test
Benzinga Newsdesk - Mar 7, 2024, 7:18AM

Friday, March 01, 2024

Keybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $28
Benzinga Newsdesk - Mar 1, 2024, 3:13PM
Scotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $37
Benzinga Newsdesk - Mar 1, 2024, 12:14PM

Thursday, February 29, 2024

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor - Feb 29, 2024, 2:00PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights - Feb 29, 2024, 12:32PM

Wednesday, February 28, 2024

Castle Bioscience Sees FY24 Revenue $235M-$240M Vs $214.693M
Benzinga Newsdesk - Feb 28, 2024, 5:14PM
Recap: Castle Biosciences Q4 Earnings
Benzinga Insights - Feb 28, 2024, 4:35PM
Castle Biosciences Q4 2023 GAAP EPS $(0.10) Beats $(0.61) Estimate, Sales $66.12M Beat $56.28M Estimate
Benzinga Newsdesk - Feb 28, 2024, 4:30PM
Earnings Scheduled For February 28, 2024
Benzinga Insights - Feb 28, 2024, 6:24AM

Tuesday, February 27, 2024

Earnings Preview For Castle Biosciences
Benzinga Insights - Feb 27, 2024, 12:01PM

Monday, February 26, 2024

Castle Biosciences Announced Publication Of A Study In Cancers Demonstrating That DecisionDx-Melanoma Provided Significantly Better Risk Stratification Than American Joint Committee On Cancer 8Th Edition Staging In Patients With Stage I Cutaneous Melanoma
Benzinga Newsdesk - Feb 26, 2024, 7:06AM

Thursday, January 18, 2024

Castle Biosciences Says New Study In Journal Of Clinical And Aesthetic Dermatology Show Its DecisionDX-SCC Test To Guide ART Decisions For Patients With Cutaneous Squamous Cell Carcinoma Could Result In Medicare Healthcare Savings Of Up To ~$972M Annually
Benzinga Newsdesk - Jan 18, 2024, 7:05AM

Sunday, January 07, 2024

Castle Biosciences Announces Preliminary Q4 And FY23 Results; Expects To Deliver More Than $210M For FY23 Total Revenue Vs $203.95M Est.; Year-End 2023 Cash, Cash Equivalents And Marketable Investment Securities Expected To Be ~$243M
Benzinga Newsdesk - Jan 7, 2024, 8:20PM

Monday, December 25, 2023

12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Dec 25, 2023, 8:05AM

Thursday, December 14, 2023

Guggenheim Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $25
Benzinga Newsdesk - Dec 14, 2023, 6:38AM

Thursday, November 23, 2023

Massive Insider Trade At Castle Biosciences
Benzinga Insights - Nov 23, 2023, 10:04AM

Wednesday, November 08, 2023

Castle Biosciences, Inc. Announces Real-World Evidence Confirms IDgenetix-Guided Medication Management Significantly Improves Response And Remission Rates In Patients With Major Depressive Disorder
Benzinga Newsdesk - Nov 8, 2023, 5:46PM

Friday, November 03, 2023

Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx-UM That Could Aid In Early Detection of Uveal Melanomas
Benzinga Newsdesk - Nov 3, 2023, 7:12AM

Thursday, November 02, 2023

Castle Biosciences Increases FY23 Revenue From $180M To $200M Vs $187.07M Est.
Benzinga Newsdesk - Nov 2, 2023, 5:59PM
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Nov 2, 2023, 5:31PM
Early Discovery Data Shows Ability Of Castle Biosciences' Pipeline Program To Distinguish Between Responders And Non-Responders To An Atopic Dermatitis Therapy
Benzinga Newsdesk - Nov 2, 2023, 5:24PM
Castle Biosciences Q3 2023 EPS $(0.26) Beats $(0.76) Estimate, Sales $61.49M Beat $48.52M Estimate
Benzinga Newsdesk - Nov 2, 2023, 4:09PM
Earnings Scheduled For November 2, 2023
Benzinga Insights - Nov 2, 2023, 4:56AM

Thursday, October 05, 2023

Castle Biosciences Announced A New Study Demonstrating DecisionDx-melanoma Outperforms A Nomogram Developed At The Memorial Sloan Kettering Cancer Center In Predicting The Risk Of Sentinel Lymph Node Positivity In Patients With Cutaneous Melanoma
Benzinga Newsdesk - Oct 5, 2023, 7:07AM

Monday, October 02, 2023

Castle Biosciences' Says New Data Shows Significant Clinical Utility Of Its Tissuecypher Barrett's Esophagus Test For Patients With Non-dysplastic Barrett's Esophagus At A Higher Risk Of Progression To High-grade Dysplasia Or Esophageal Adenocarcinoma
Benzinga Newsdesk - Oct 2, 2023, 7:11AM

Thursday, September 14, 2023

Castle Biosciences TissueCypher Barrett's Esophagus Test Outperformed Standard Of Care In Risk-Stratifying Patients With Barrett's Esophagus
Benzinga Newsdesk - Sep 14, 2023, 7:03AM

Sunday, September 10, 2023

Castle Biosciences Announced Late Saturday, Drug-Drug Interactions And Lifestyle Factors With Drug-Gene Interactions Provided By Castle's' IDgenetix Test Impacted the Number Of Drug Recommendations For Patients With Moderate to Severe Depression
Charles Gross - Sep 10, 2023, 10:44AM

Monday, August 07, 2023

Castle Biosciences Says New Study Published In The American Journal Of Gastroenterology Shows That TissueCypher Barrett's Esophagus Test Can Improve Management Decisions For Patients With Low-grade Dysplasia To Improve Health Outcomes
Benzinga Newsdesk - Aug 7, 2023, 7:16AM

Friday, August 04, 2023

Keybanc Maintains Overweight on Castle Biosciences, Lowers Price Target to $25
Benzinga Newsdesk - Aug 4, 2023, 4:32AM

Thursday, August 03, 2023

Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
Lisa Levin - Aug 3, 2023, 10:57AM

Wednesday, August 02, 2023

Castle Biosciences Sees FY23 Revenue At Least $180M
Benzinga Newsdesk - Aug 2, 2023, 5:23PM
Castle Biosciences Q2 EPS $(0.70) Beats $(1.01) Estimate, Sales $50.14M Beat $43.51M Estimate
Benzinga Newsdesk - Aug 2, 2023, 4:27PM
Earnings Scheduled For August 2, 2023
Benzinga Insights - Aug 2, 2023, 8:45AM

Tuesday, August 01, 2023

Castle Biosciences's Earnings: A Preview
Benzinga Insights - Aug 1, 2023, 1:02PM

Wednesday, July 12, 2023

Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Jul 12, 2023, 12:53PM
Director of Castle Biosciences Makes $1.02M Sale
Benzinga Insights - Jul 12, 2023, 11:02AM

Monday, July 10, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Jul 10, 2023, 1:37PM

Friday, July 07, 2023

Castle Biosciences shares are trading higher following a Medicare coverage policy reversal by Novitas related to DecisionDx.
Benzinga Newsdesk - Jul 7, 2023, 3:32PM
Analyst Expectations for Castle Biosciences's Future
Benzinga Insights - Jul 7, 2023, 3:00PM
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights - Jul 7, 2023, 1:37PM
Why iMedia Brands Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Jul 7, 2023, 12:55PM
Alibaba, Kura Sushi USA And Other Big Stocks Moving Higher On Friday
Lisa Levin - Jul 7, 2023, 10:16AM
Dow Drops 75 Points; US Economy Adds 209,000 Jobs In June
Lisa Levin - Jul 7, 2023, 9:48AM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Jul 7, 2023, 9:12AM
Lake Street Reiterates Buy on Castle Biosciences, Maintains $32 Price Target
Benzinga Newsdesk - Jul 7, 2023, 8:47AM
Castle Biosciences To Present New DecisionDx-SCC And DecisionDx-melanoma Data At The American Head & Neck Society's International Conference On Head And Neck Cancer
Benzinga Newsdesk - Jul 7, 2023, 7:03AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved